Phase 1/2 Trial Confirms Safety With Repeated Dosing Supporting Further Development in Early-stage Disease and Combination Treatment Settings ATLANTA, GA - December 8, 2025 (NEWMEDIAWIRE) - GeoVax ...
Patent Protects Novel Application of Gedeptin Therapy Across Multiple Solid Tumor Types; Supports Expansion of Gedeptin ...
The U.S. commercial launch of LYMPHIR (denileukin diftitox-cxdl), a novel cancer immunotherapy for adults with relapsed or ...
Financing includes participation from leading institutional investors including Janus Henderson Investors, Brahma Capital, Biotrack Capital, Cormorant Asset Management, OrbiMed, Plaisance Capital ...
As big pharmas including Takeda and Novo Nordisk flee the cell therapy space and smaller biotechs shutter their operations, ...
An Institute for Value-Based Medicine ® event held in New Haven, Connecticut, on October 30, 2025, brought together a diverse ...
The addition of tucatinib to first-line trastuzumab plus pertuzumab delayed disease progression among a cohort of women with ...
In patients naïve to HER2-targeted therapy, the objective response rate was 71% with a median duration of response of 9.2 months.
Mycosis fungoides, the most prevalent CTCL subtype, accounts for the majority of cases. Although early-stage disease has a five-year survival rate of roughly 88%, it is a chronic cancer with ...
Axatilimab showed a consistent safety profile in cGVHD patients, with no new safety signals and a decrease in TEAEs over time. The AGAVE-201 trial led to FDA approval of axatilimab at 0.3 mg/kg every ...
The therapeutic landscape for hepatocellular carcinoma (HCC) has been revolutionized by the advent of molecular targeted therapies and immune ...
A study by researchers at the D’Or Institute for Research and Education in Rio de Janeiro, Brazil, suggests that blocking the microRNA known as miR-21 may significantly slow the growth and spread of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results